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Melanoma is a form of skin cancer, arising from epidermal cells of the melanocyte lineage, which 
undergo a series of transformations and genetic alterations that may give rise to both pigmented and 
unpigmented melanoma. Melanoma represents 4% of all skin cancers but due to its aggressive nature, 
it accounts for 80% of death among skin cancer patients. South Africa has a melanoma incidence rate 
that is second worldwide to only Australia. In melanoma; non-metastatic primary tumours are treated 
by surgical resection. However, metastatic melanoma is highly resistant to conventional radio and 
chemotherapy, thus reducing the median life of patient’s diagnosis with the metastatic form to about 
7-9months. Given the implications of the pigment in failure of chemotherapy, two human metastatic 
pigmented and unpigmented melanoma cell lines were used to investigate the mechanisms underlying 
chemo-resistance. During the course of this study, the first aim was to determine the concentration of 
the chemotherapeutic drug dacarbazine (DTIC) causing fifty percent decrease in melanoma cell 
viability (LD50), then to investigate the possible synergism of hypericin activated-photodynamic 
therapy in reducing (HYP-PDT) melanoma cell viability, when combined with chemotherapy. In 
addition we wanted to assess the morphology and the clonogenic capacity of the melanoma cells, after 
the different treatments and further investigate the ATP-binding cassette (ABC) transporters 
(ABCB5/1 & ABCG2) expression profile, before and after chemotherapeutic (DTIC) and 
combination therapy (DTIC+HYP-PDT) treatments. The results obtained from the cell viability 
assays, showed that pigmented melanoma was more resistant than unpigmented melanoma after the 
different treatments at both 24 & 48 hour time points. However, only 48 hour DTIC (1250µM) 
treatment was shown to kill fifty percent of unpigmented melanoma, while being sub-lethal to their 
pigmented counterpart. Moreover, at 24 hours, resistance of the pigmented melanoma to 
chemotherapy was abrogated upon combination therapy treatment (DTIC+ HYP-PDT). This was 
perfectly correlating with the cell shrinkage (completely disrupted morphology and nuclear aggregate 
formation in unpigmented cells) and the clonogenic assay, where pigmented melanoma was shown to 
be more resistant to the chemotherapeutic treatment when compared to their unpigmented counterpart. 
Significantly, at both 24 and 48 hour time points, HYP-PDT and combination therapies (DTIC+ HYP-
PDT) were able to completely suppress the clonogenic capacity of the two metastatic melanoma cells. 
Lastly, no significant differences in ABCG2/ABCB1/ABCB5 transporter protein expression (at 24 
hours) upon DTIC treatment were revealed.  
Overall, these results show that melanoma resistance to chemotherapy and combination 
phototherapies are dependent on the pigmented phenotype of melanoma cells. This work has direct 




Chapter 1: Literature review 
 
1.1. MELANOMA PREVALENCE AND TREATMENTS: 
 Skin cancer is the most common cancer worldwide1. Of the skin cancers, melanoma 
represents the most aggressive, malignant phenotype resulting from a genetic and/or 
environmental-induced change to epidermal skin melanocytes. The chief environmental 
factor remains solar ultraviolet radiation  (UV)2.The melanocytes are located in the basal 
layer of the skin epidermis, where they produce the pigment melanin, which protects the skin 
from UV damage (Figure 1). However, it is within the double membrane vesicles called the 
melanosomes, that melanin are synthesized from the amino acid tyrosine. This, occurs (Dark 
skin) through the resultant rate-limiting, enzymatic action of the melanocytic enzyme 
tyrosinase, and the co-ordinated action of tyrosinase related protein 1 (TYRP1) and 2 
(TYRP2), resulting in eumelanin production (black-brownish coloured pigment mostly 
occurring in black) in a processs known as melanogenesis, as opposed to the pheomelanin 
pigment ( yellow-reddish colour) production, which results from nucleophilic oxidation of L-
cysteine in presence of dihydroxyphenylalanine (DOPA)3,4 .  Clinically, melanoma can be 
described as pigmented, characterized by black lesions resulting from melanin accumulation, 
or unpigmented reflecting a less differentiated cell with less pigment production5. In 2000,  it 
was reported that out of 132 000 diagnosed melanoma cases worldwide, melanoma caused 
37 000 deaths,  highlighting the aggressiveness of the disease6. In Europe melanoma caused 
about 26% of deaths out of the 35000 diagnosed melanoma patients, with shocking statistics 
recorded in New Zealand and Australia (highest incidence), where melanoma incidence is 
double the highest incidence rates in Europe, mainly affecting European migrants6.  South 
Africa after Australia, has the second highest incidence of melanoma where, 65 and 69 (in the 
Cape region) new cases respectively per year out of a population of 100, 000 Caucasians are 
diagnosed7. This translates to 1 in 1429 people who will develop malignant melanoma 
(CANSA Cancer association of South Africa www.melanoma.co.za/D_doccnr _MFS.asp).  
Interestingly, due to increased public awareness and better dermatological reporting, the trend 
in South Africa seems to reflect increased cases being reported among the South African 
black community.  
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Despite the gold standard for melanoma treatment remaining early detection, surgical 
excision and adjuvant therapy; the prognosis of metastatic melanoma remains very poor. 
Once melanomas reach the advanced metastatic stage, they become highly resistant to 
conventional radiotherapy and chemotherapy8,9,10. At this point, melanoma patients are left 
with a median survival approximating 8 months11,12,5 and chemotherapy so far has been  
unsuccessful in improving this survival. Other therapeutic options at this point include 
therapies such as immunotherapy, biochemotherapy and radiotherapy13,14. 
 
 
Figure 1:  Human skin layers and cell types (adapted from15) 
 
Currently, the treatment regimens rely on chemotherapy as the best option post-resection with 
the first U.S food and drug administration approved drug Dacarbazine (DTIC) (1975), used 
as the standard treatment of metastatic melanoma16,13,14 To date however, six drugs have been 
approved by the FDA, for the treatment of metastatic melanoma -  dacarbazine (FDA 
approved in 1975)14, interleukin-2 (IL-2), vemurafenib, ipilimumab, dabrafenib, and 
trametinib. Vemurafenib and ipilimumab were  FDA approved in 2011, while dabrafenib and 
trametinib were FDA  approved in 201317. Very recently (2014), anti-program cell death-1 
(Anti-PD-1), has also been approved for treatment of patients with advanced melanoma18. 
14 
 
To date single agent chemotherapy using DTIC, have  produced the best therapeutic outcome 
with 15% of patients responding to the therapy, although less than 2% survive 6 years post-
treatment14.  Other proto-oncogene B-Raf (BRAF) inhibiting drugs such as doxorubicin, 
cisplatin, paclitaxel as well as vemurafenib (FDA approved in 2011)19 have also been used in 
the treatment of melanoma and their failures relate to increased cellular toxicity to the 
surrounding normal cells, development of resistance,9  and their  inability to extend survival 
rate when compared to dacarbazine alone14,9,20,2122,13. Given these failures, combination 
therapies such as biochemotherapy (cytotoxic agents with immunotherapeutic treatment) 
emerged, in order to attempt to increase the response and survival rates of patients. Thus far, 
this has shown to be unsuccessful due to the unchanged  survival rate of patients and its 
requirement for safety, of lower dose of IL-2 which compromise the eventuality of complete 
remission14. However, other combination therapies such as DTIC and ipilimumab showed 
improved patient survival compared to DTIC alone23.  
Although  not yet  approved by the FDA for melanoma treatment, photodynamic therapy 
(combination of photosensitizer and visible light)  has been effective in the treatment of non-
melanoma skin cancer and other cancers24,25. It has been tested in vitro for melanoma 
treatment with promising results, as reported by our laboratory which showed that it 
potentiated a more pronounced  killing of metastatic unpigmented cells, when compared to 
their pigmented counterparts26,27. Moreover,  depigmentation of a pigmented metastatic 
melanoma rendered them more susceptible to cell death induced by the photodynamic 
treatment (PDT)27. This differential response was suggested to be attributed to the pigment 
melanin, which can affect the PDT efficiency, by either competing for photo-energy or by 
acting as an antioxidant reducing the reactive oxygen species (ROS) produced by PDT, and 
in turn, reducing cell death5,27. Attempts to circumvent the death resistance, have been tried in 
melanoma and other cancers by combining PDT and chemotherapy, which have led to 
promising synergistic actions of the therapies28,29,30. In order to understand the failure to the 
diverse treatments in metastatic melanoma, it would be of great relevance to firstly elucidate 
the mechanism of actions of the individual therapy (chemotherapy and PDT) and secondly, to 
understand the resistance mechanisms such as those related to for example the expression of 




1.2. PHOTODYNAMIC THERAPY: 
1.2.1. Mechanism of action: 
It is now well reported that PDT is  successful in the treatment of multiple cancers including 
non-melanoma skin cancers1,31,32,33. However, in melanoma, PDT has not yet been approved 
as a post-resection adjuvant therapy or in combination with other therapies upon metastatic 
diagnoses. PDT is a minimally invasive two-stage treatment, which involves topical or 
systemic administration of a photosensitizer (PS), followed by illumination of the tumour or 
tumorigenic cells with visible light in the presence of molecular oxygen 34,24. Upon light 
activation at a specific wavelength, the PS is raised from an unexcited ground state to a very 
unstable excited triplet state, through absorption of energy in the form of photons. In its 
triplet state, the PS is unstable and can decay back to its ground state, hence releasing energy 
to ground state molecular oxygen. This will either result in singlet oxygen (1O2) formation 
through a type II photochemical reaction, or upon electron transfer in superoxide anion 
radical (O-2) and hydroxyl radical (OH.) formation via a type I photochemical reaction24,34 
(see Figure 2).  
These ROS have a very short half-life (nanoseconds), and exert their cytotoxic effects in the 
vicinity of their production, as they can diffuse up to only 20nm in cells34,35. Upon 
production,  ROS has been shown to be responsible for tumour destruction, activation of anti-
tumour immune responses, as well as tumour vasculature damage32,34. It follows then that the 
subcellular localization of the PS is of great relevance, given that ROS production may well 
cause oxidization of biological molecules such as lipids, proteins and nucleic acids resulting 






Figure 2: The “trinity” (Photosensitizer, oxygen and light) of photodynamic therapy (PDT).  
The photosensitizer moves from the ground singlet state (S0) to an excited singlet state (S1) upon 
absorption of light. The molecule in S1 may undergo intersystem crossing to an excited triplet state 
(T1) and then either form radicals via Type I reactions or transfer its energy to molecular oxygen, 
forming singlet oxygen (1O2), via Type II reactions. (ns: nanoseconds, μs: microseconds, nm: 
nanometres, eV: electron volts) modified Jablonski diagram, taken from24. 
 
 
1.2.2. Photodynamic therapy and melanoma 
PDT is a favorable therapy, which has proven to have negligible toxicity towards normal 
tissue39,40, reduced systemic effects, and scarcity of intrinsic or acquired resistance 
mechanisms. However, in melanoma which is considered to be one of the most unresponsive 
cancer to known therapies, the use of PDT as a possible  adjuvant therapy for the treatment of 
advanced stages (metastatic) has been investigated, with promising results5,34. In 2004,  
Sheleg et al. reported that complete remission was achieved with no recurrence, on melanoma 
patients, who were treated with double exposure to  Chlorin e6 (Ce6)+ PDT41. This was an 
interesting result, which will necessitate further clinical studies for approval of PDT as 
melanoma treatment, given the sporadic reports. However, most of the cell death induced 
mechanisms observed upon melanoma treatment with PDT, involved apoptosis42,43. In 
another study Saczko and colleagues (2005), showed that PDT using photofrin as PS induced 
apoptosis in 90% of melanoma cells and that the efficacy of the therapy mainly relied on the 
PS concentration and time of exposure43. This was further confirmed by Robertson et al 
(2010), who showed that activation of 5-aminolevulinic-acid (5-ALA) and 
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metallophthalocyanine with a light of 680nm and 630nm resulted in growth inhibition of 
melanoma cells through apoptosis activation44. In addition, subcellular localisation of the PS 
will influence the mode of cell death resulting after PDT, as Choramanska et al (2012) 
showed that disturbance of the mitochondrial membrane caused by photofrin in Me45 cells 
induced apoptosis45.This was recently further emphasized by  Kleeman et al. (2014) who 
found co-localisation of hypericin (PS) within the endoplasmic reticulum (ER), mitochondria, 
lysosomes and melanosomes42.  Upon activation with ultraviolet radiation A (UVA), 
apoptosis was found to be induced via both a caspase-dependent (pigmented & unpigmented 
melanoma) and independent (moderately pigmented melanoma) pathway. Moreover, earlier 
work  from the same group showed that hypericin-based PDT treatment induced different 
modes of cell death given the cell types and PS localisation42,46.  
In melanocytes and pigmented melanoma, a necrotic mode of cell death was found as 
opposed to apoptosis which was observed in keratinocytes and unpigmented melanoma 
treated with HYP-PDT46.  From these observations, it was deduced that the necrotic mode of 
cells death (melanocytes and pigmented melanoma), could be due to increase permeability of 
the melanosomal membranes, caused by increased ROS production resulting from hypericin 
activation, which subsequently caused leakage of melanogenesis by-products into the 
cytoplasm46. However, the induction of apoptosis (the moderate /unpigmented melanoma and 
keratinocytes) was well correlated with a disturbance of the mitochondrial tubular network as 
well as the loss of structural details of the ER42,46. However, no structural modifications were 
observed in the lysosomes and melanosomes. This observation could well relate to an 
inherent cellular resistance mechanism to the PDT treatment since both Sharma and Davids 
(2011) and Chen et al. (2009) demonstrated the protective role of melanin and melanosomes 
to PDT and chemotherapy27,47. This contribution of melanin in reducing PDT efficacy was 
further reinforced by the demonstration that depigmentation of pigmented melanoma cells 
(previously resistant to PDT) sensitized them to PDT27. In vivo confirmation of this was 
shown where, using a mouse model,  pigmented melanoma was found to be less responsive to 





Interestingly, the trapping property of anticancer drugs by melanosomes in melanomas (Chen 
et al., 2009) could be attributed to the ATP-binding cassette  (ABC) transporter proteins, 
located in the melanosomal membrane which actively pump toxic substances into the 
melanosomes for neutralization and thus reduce the effectiveness of the treatment 34,47. This 
subcellular localization and conservation of organellar membrane integrity is therefore  
important as leakage of the cytosolic constituent into the extracellular space upon necrotic 
cell death activation (upon-plasma membrane damage), can result in a robust anti-tumour 
immune response46,49,50. In apoptosis, these cytosolic constituents will be sequestered by 
intact membranes of apoptotic cells, which are phagocytosed by surrounding macrophages 
51,52. Lastly, studies on mice showed that PDT may induce tumour-associated vasculature 
damage, which prevent metastases and subsequent tumour regression53,54.  In order to 
improve PDT treatment in melanoma, several parameters aimed at overcoming resistance will 
necessitate further investigation. These may include: interventions which can temporarily 
reduce the amount or the pigmentation status of melanoma; the discovery of highly active PS 
absorbing in the 700–800-nm near infrared spectral region; immunotherapy approaches that 
can take advantage of the ability of PDT to activate the host immune system to the treated 
tumour, use of compounds that can reverse or inhibit drug-efflux of PS and finally combining 
PDT with other therapies such as chemotherapy. 
1.3. HYPERICIN: 
The success of PDT is related to the photosensitizer, presence of oxygen in the immediate 
environment and the induction of ROS through an appropriate photoactivation at a specific 
wavelength of light. In this study, we used hypericin, a natural photosensitizer, 
biosynthesised within the dark glands of the petals and leaves of the St John’s Wort plant 
(Hypericum perforatum) (Figure 3A&B) 55,56. It belongs to the chemical class of 
naphtodianthrones (Figure 3 C) and can be chemically synthesized through conversion of 
emodin to hypericin using Hyp-1 enzyme, yielding approximately 84.6% efficient conversion 
when overexpressed in E.coli57,58.  This is a favourable  alternative, as direct extraction from 
H.perforatum, produces a low yield of hypericin due to the low occurrence of the  
naphtodianthrones (0.05-0.3%)59, which is costly and necessitates multiple cycles for 
purification, while requiring  fast handling of materials58. Hypericin absorbs in both 300-
400nm (ultraviolet) (Figure 3D) and 500- 600nm (white light)60 range, with an optimal 
absorption peak at 563nm and emission at 600nm (Figure 3D)61. However, its 
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photosensitizing effect was discovered, when grazing animal feeding on the plants, developed 
non-desirous photosensitization of the skin upon sunlight exposure, through a biological 
reaction called hypericism 56.     
 
 
Figure 3: St John’s Wort (Hypericum perforatum.) 
(A)Hypericum perforatum plant and its (B) dark glands found in the leaves and petals, which 
(C) Hypericin’s chemical structure, (D) hypericin absorbance spectrum (Internet source). 
  
In humans, hypericin has been used for the treatment of various conditions including  
depression, anxiety, restlessness and sleeping disorders62,63. Moreover, its fluorescent 
properties have enabled the visualization of malignant tumour such as gliomas in a process 
known as photodiagnosis64. In addition,  its photosensitizing properties have been widely 
used in treating several cancers (GH4C1 rat adenoma and human P3 squamous carcinoma 
cells  )65,66,67. Hypericin has desirable properties as a photosensitizer, since it is not cytotoxic 
in the dark; has a low photobleaching, intense absorption spectrum in the visible light region, 
large excitation range  and is rapidly cleared from the body while being preferentially 
retained within the tumour68,69,70,71.  Due to its hydrophobic nature, hypericin  is  mainly 
absorbed within tumours cells through passive diffusion or by forming complex with the low-
density-lipoproteins (LDL), which is overexpressed in the majority of cancer cells56,70,72,. 
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During photodynamic treatment, hypericin mainly exercises its cytotoxic effect through 
production of singlet oxygen (102)73,74, superoxide anion along with other ROS. In addition, 
production of ROS by hypericin has been shown to induce cell death through mechanisms 
such as apoptosis, necrosis and autophagy 42, 68,75,76,77. This has been reported to be due to 
hypericin’s subcellular localization upon PDT treatment36,37,42,78. Kessel and colleagues 
(1997)79 found that localisation of etiopurpurin (PS) within the mitochondria and lysosomes 
resulted in a rapid apoptotic response. This was opposed to its analogue where a delayed 
apoptosis was observed due to its partial membranous localization, which promoted 
predisposition for necrotic cell death79. Other studies however reported on  resistance to 
hypericin PDT treatment in melanoma and adenocarcinoma treatment26,27,33. In order to 
circumvent this HYP-PDT resistance,  several attempts have been made, combining HYP-
PDT with chemotherapeutic drug such as temozolomide (an analogue of dacarbazine), where 
it has been shown to increase tumour inhibitory growth potential on glioblastoma cells80.This 
combined therapy, did not only improve the efficacy of the treatment, but also lowered the 
dose of the chemotherapeutic drugs, which  resulted in reduced side effects. This study was 
confirmed by another group, which also found that combining chemotherapy and 
photodynamic therapy was more effective at killing human melanoma cells. However, this 
was achieved, through the use of the photosensitizing property of a mitoxantrone 
chemotherapeutic drug, resulting in lower light intensity29. In order to establish such a 
combination for treating the deadly disease that is melanoma, one would have to be selective 
in combining the hypericin with a good chemotherapeutic drug, which has currently been 
shown to be effective at treating melanoma. For this reason, this project chose the alkylating 





1.4. DACARBAZINE (DTIC) AND MELANOMA 
 
Figure 4: Dacarbazine chemical structure.  
 
 
Dacarbazine (DTIC) is the only chemotherapeutic drug approved since 1975 (Figure 4), by 
the Food and Drug Administration (FDA) for the treatment  of malignant melanoma14. DTIC 
is an alkylating agent, which exercises its cytotoxic effect by adding an alkyl group to DNA, 
thus causing DNA lesion formations, halting DNA synthesis and resulting in cell growth 
arrest and cell death81,82. During this process it is administered as a prodrug cytotoxic agent 
(DTIC), which has alkylating activity, resulting in generation of methyl DNA lesions 
inducing cell death.83,84,85. In melanoma, among the numerous methyl DNA lesions caused by 
DTIC, the most cytotoxic is the 0-6-methylguanine (0-6-meG) 83,86. These cytotoxic lesions 
(0-6-meG) can be repaired by 0-6-methylguanine-DNA-methyltransferase (MGMT), which 
may affect DTIC efficacy when overexpressed in cancer cells86,87. From this observation, it 
might be implied that DTIC efficacy may rely on low MGMT repair and high activity of 
mismatches repair enzymes as it has been shown in melanoma83. 
Clinically, DTIC is mostly administered intravenously with a dose of 150 to 200mg/m2 over 
five days14. However, single dose administration of 800 to 1000 mg/m2 repeated every 3 to 4 
weeks, is more suitable and well tolerated by patients14. Using this regime, a 15.3% objective 
response rate was achieved, in trials involving 1390 patients. Amongst this, 4.2% had a 
complete response as opposed to the remaining 11.1% where partial response was observed14. 
To date it’s been the most effective  chemotherapeutic drug in melanoma treatment, since it 
has shown superiority in patient survival, when compared to other treatment regimens in 
phase III trials14,88. Recently, Hervieu and colleagues (2013) showed in an in vivo experiment 
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that DTIC may induce tumour destruction by local activation of natural killer (NK) and T 
cells in melanoma89. However, the problem of chemoresistance remains. In order to 
overcome this chemoresistance, Kamila and colleagues (2013) showed that combining DTIC 
and parthenolide, resulted in a synergistic-inducing cell cycle arrest and apoptosis82. 
Moreover, this combination apart from reducing the number of viable cells, led to the 
eradication of the self-renewing capacity (clonogenic activity) of the melanoma cells, which 
DITC could not abrogate when used alone. Furthermore, when used alone DTIC  (apart from 
being less effective on heterogeneous melanoma when compared to A375) induced increased 
secretion of vascular endothelial growth factor (VEGF), which promoted vascularisation 
favouring  metastasis and relapse after treatment.  However, in combination with 
parthenolide, the VEGF secretion was decreased, as well as its baseline level. Although this 
combination showed synergism, it however failed to reduce significantly the interleukin-8 
expression (IL-8), whose overexpression has been shown to contribute to  melanoma 
resistance to temozolomide treatment, a DTIC analogue82,90. Valero and colleagues (2010) 
also showed in an in vivo mouse model, that combining DTIC with dimethylfumarate; 
resulted in reduced lymph node metastasis91. Earlier, Thrall and colleagues (1991) showed 
that pre-treatment of murine melanoma cells with buthionine sulfoximine (50µM), reduced 
90% of glutathione level  (GSH) within the cells (which was fivefold higher in melanoma 
compared to melanocytes), causing an increased growth inhibitory effect on the cells92. 
Although these resistance mechanisms are crucial in improving DTIC treatment, other factors 
contributing to lower intracellular accumulation of DTIC below its cytotoxic threshold have 
been identified in melanoma13,93. This has been attributed to a family of ABC transporters, 
which are overexpressed in melanoma, and which upon DTIC treatment, is enriched in cells 
called a “side population”. These cells have self-renewing capacity and the ability to grow 
under hypoxic conditions. Lastly, these cells have the potential to re-form the heterogeneous 
parental tumour, causing the relapse of treated patients observed clinically93,94. The study of 






1.5. MELANOMA THERAPY RESISTANCE AND ABC 
TRANSPORTERS 
1.5.1.  ABC transporters and chemoresistance 
Speculation over what contributes to the cellular chemoresistance in melanoma has led to 
numerous theories. Of late, focus has shifted to the one feature that sets melanocytes and 
hence melanoma apart from other cell types, the melanosomes. These are membrane-bound 
organelles originating from the lysosomal lineage which seems to confer chemoresistance 
through a complex mechanism of drug trapping and export95. The central players in this 
mechanism are said to be the ATP-binding cassette (ABC) transporters which actively 
transport cytotoxic substances out of cells96. In humans, ABC transporters possess 48 genes, 
which are split into seven different subfamilies based on their domains and amino acid 
homology97,98 (see Table 1). These transporters  are ubiquitously expressed and located in cell 
membranes and multiple subcellular organelles (lysosomes, peroxisome, Golgi apparatus, 
mitochondria, endoplasmic reticulum), where they transport various molecules across the 
biological membranes in an ATP-dependent manner5,96,99. They can be categorized into two 
groups, consisting of the ABC “importers” mainly found in prokaryotes where they function 
to import nutrients within the cells and the eukaryotic ABC “exporters” whose function is 
tofacilitate the secretion of toxic compounds and various molecules out of the cells99.  
In humans however, each ABC transporter (exporter) contains a pair of ATP-binding 
domains referred to as a  nucleotide binding fold (NBF) which is located within the 
cytoplasm and a pair of transmembrane domains (TM) embedded within the cell membrane 









 Table 1: Overview of ABC transporters’ expression profile in cell lines. 
 
Transporter Cell Line Location Expression Drug Reference 







CS, H14, JR8 7p21 Cytoplasm Doxorubicin 100 
ABCC1 
(MRP1) 

















ABCB5 HEM; G3361; 
CD133 









4q22 Cell surface Vemurafenib 102 


























HT-29; HL60 16p13.1 Cell surface hypericin 33 
ABCG2 
(BCRP) 




During the efflux of cytotoxic molecules,  a pair  of ATP molecules bind to a portion of each 
NBF, which subsequently merges and undergoes a structural conformational change which  
results in  ATP hydrolysis98. This ATP hydrolysis eventually leads to the release of energy, 
which is subsequently used to transfer the cytotoxic molecules (substrate) from the inner part 
of the membrane to the outer part through the two TMs (Figure 5)98. 
Recently, melanomas have been shown to express ABC transporters, which lower the 
intracellular accumulation of cytotoxic drugs 9,107. Moreover, these transporters have been 
demonstrated to be highly expressed in highly tumorigenic subpopulations of melanoma and 
a number of groups have therefore suggested that they may be potential markers of melanoma 
stem cells9,22,108,109. One of these include the ABCB5 transporter, which seems to be 
characteristic of the resistant population and its expression results in therapeutic relapses, by 
re-forming the parental tumor along with a population of a more aggressive phenotype110,111. 
Additionally, in melanoma a population of cells overexpressing the  ABCB5, ABCB1 and 
ABCB8 transporters, were  found to be resistant to chemotherapeutic treatments with 
doxorubicin and dacarbazine9,14,82,93,101,103,112. Also, this ABCB5 and ABCB1 overexpression 
was found to correlate with cancer progression and aggressiveness.  
Moreover, it has recently been reported that resistant populations overexpressing ABCB1/5 
transporters have stem cell-like properties. These properties include self-renewal capacity 
(clonogenic capacity), spheres forming ability as well as yielding differentiated progeny and 
a population that can efflux dyes (reflective of the resistant population overexpressing the 
ABC transporter, which export dyes such as  Rhodamine 123 or Hoechst)93,110. This is really 
important, since this resistant population has the ability to recapitulate the phenotype of the 
parental tumour, contributing to the heterogeneity of the tumour which can be associated with 
the relapse observed clinically93,110.  Finally, reports have shown the ability of this resistant 
population  to grow under aggravating condition such as hypoxia, through up-regulation of 
genes such as hypoxia-inducing factor 1α (HIF1α) under the influence of its upstream 
regulator, PI3K/AKT93,110. However, a report has shown that overexpression of transporters 
such as ABCC1 and ABCG2 in adenocarcinoma cancer reduced HYP-PDT killing efficiency, 
as well as other photosensitizers. 30, 103,113, ,114,. This is of particular interest as, recent work in 
our   lab has shown that the photosensitizer hypericin co-localizes with melanosomes 
involved in melanoma resistance to HYP-PDT.  In order to combine the chemotherapeutic 
treatment with   the possible adjunctive photodynamic therapy, one may have to investigate 
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what is the ABC transporter profile in resistance to this therapeutic treatment (PDT) in skin 
cancer. 
 
Figure 5: Diagram of an ABC transporter.   
(A). A prototypical ABC transporter is shown with two sets of transmenbrane domains (TM, blue) 
and two nucleotide binding domains (NBF, red), free ATP molecules and substrate molecules in the 
inner membrane leaflet (light Blue). (B) Upon binding of ATP, the NBFs are joined, leading to a 
conformational change, and the movement of the substrate molecule98. 
 
1.5.2. ABC transporters and photodynamic therapy resistance 
Photodynamic therapy  has produced promising results in melanoma, however resistance 
soon developed as a result of ABCG2 transporter overexpression, which has shown to lead to 
an efflux of photosensitizers including: hypericin, pheophorbide a, pyropheophorbide a, 
chlorin e6, 5-aminolevulinic acid (5-ALA) and protoporphyrin IX 103,114,115 ,116. 
 The ABCG2 is a  half  transporter (consisting of one NBF and TM) and is a member of the 
heme efflux system, which becomes functional upon dimerization, and hence effluxes various 
molecules103. The importance and specificity of the ABCG2 transporter to efflux 
photosensitizers was emphasized in a recent study where it was shown that its inhibition with 
non-toxic Ko-134 (analogue of fumitremorgin C)103, increased the efficacy of PDT in human 
keratinocytes (HaCat cells). This result was supported by Liu et al.(2007) who showed that 
inhibition of the ABCG2 transporters using imatinib mesylates, resulted in increased 
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intracellular accumulation of the PS (2-devinyl-pyropheophorbide a, protoporhyrin IX and 
benzoporphyrin derivative monoacid ring A) within basal cell carcinoma cells (BCC) 
(ABCG2 positive) and not within squamous cell carcinomas (ABCG2 negative). This 
increase of PS within the BCC, was correlating with increased phototoxicity and selectivity, 
resulting in tumour destruction105. 
A further aspect that contributes significantly to the therapeutic efficacy of a treatment 
modality such as PDT is the intracellular localization of the photosensitizers. The fact that 
ABC transporters are found localized in the subcellular membranes (mitochondria, 
lysosomes, peroxisomes, melanosomes and Golgi apparatus) mean that their roles in 
therapeutic resistance with respect to organellar localization cannot be underestimated and 
needs to be investigated. One example is their localization in melanocyte-specific organelles 
called melanosomes. These organelles house the process of melanogenesis and subsequent 
accumulation of the pigment melanin. The melanosomes are surrounded by a double 
membrane due to the toxic intermediates produced during the process of forming melanin. 
Our lab, and others have shown that pigmented melanoma was more resistant to HYP-PDT, 
when compared to unpigmented melanoma cells and suggested that this was partly due to the 
pigment melanin, as temporary removal of the melanin using Kojic acid, sensitized the cells 
to the HYP-PDT treatment27. This correlated with increased ROS, thus unveiling the 
scavenging property of the pigment melanin and mature melanosomes27. This differential 
sensitivity to PDT was further corroborated by both Sparsa et al. (2013) and Jend et al. (2009) 
who showed that the combination of the pigment melanin and up-regulation of ABCG2, 
caused resistance in colon cancer to HYP-PDT113, 117. Upon pre-treatment with proadifen 
(affecting ABCG2 function), this resistance was reversed due to increased intracellular level 
of HYP and ROS, which subsequently resulted in mitochondrial membrane damage and 
concomitant cell death113. A further study contributing to the hypothesis of ABC transporters 
expressed on subcellular organelle membranes being important to cancer treatment 
resistance, was published by Goler-Baron and Adar et al. (2012) who demonstrated that 
resistance in breast cancer was developed, when ABCG2-rich extracellular vesicles and 
lysosomes trapped the photosensitive drugs imidazoacridinone and topotecan (In breast 
cancer), thus preventing them from reaching their therapeutic targets30,118. Reversal of this 
resistance was achieved, upon illumination of these ABCG2-rich extracellular vesicles and 
the lysosomes containing the drugs, resulting into severe membranous damage, due to the 
production of ROS30. 
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 In summary, approaches to overcome the ABC transporters in skin cancer resistance to PDT 
are needed. One of these approaches could be combination therapy, as Jin-Chul and 
colleagues (2013) showed that combining Cisplatin to 5-ALA photodynamic therapy (both 
efflux by ABCG2), led to greater tumour destruction both in vitro and in vivo, when 
compared to individual treatments in squamous cell carcinoma28. This had the advantage of 
not only having greater tumour destruction, but also to lower the concentration of the 
chemotherapeutic drug (thus, lowering of side effects)28. Other treatments may involve pre-
treatment of melanoma or non-melanoma skin cancer (NMSC) tumours with proadifen or 
verapamil (ABCG2 transporter inhibitor), and then performing HYP-PDT or pre-treating the 
cells with bafilomycin A1 to prevent lysosomal localization of the drugs followed by 
application of PDT treatment. 
1.6. AIM OF THE STUDY: 
Due to the heterogeneity of melanomas at a molecular and cellular level, and the paucity of 
information regarding their ABC transporters status, this study hypothesizes that 
chemoresistance is integrally related to the ABC transporter expression in these cells and that 
a synergistic action between DTIC and PDT can influence the chemoresistance properties of 
melanoma cells and thus render them more susceptible to cell death.  
In order to realize the above aim, the following objectives were set out:  
1) To establish the DTIC concentration killing fifty percent (LD50) of pigmented and 
unpigmented metastatic human melanoma cell lines. 
2) To investigate the cytotoxic effect of the combination of DTIC and HYP-PDT in the 
melanoma cell lines 
3) To determine the protein expression of the ABC transporters in response to single 
(PDT only) and combination (PDT+DTIC) therapies.  
4) To investigate the clonogenic potential of the pigmented and unpigmented melanoma 




Chapter 2: Materials and Methods 
2.1. CELL CULTURE 
For all experiments, human melanoma cell lines were used. The human A375, unpigmented 
melanoma cell lines were obtained from the American Type Culture Collection (ATCC, 
USA), while the pigmented, UCT-Mel-1 was originally isolated from the metastatic lymph 
node of a patient at Groote Schuur Hospital (GSH), Cape Town, South Africa. The HeLa cell 
line (Cervical cancer cell lines) was a generous gift from Prof.Virna Leaner, who obtained the 
cells from ATCC. However, the 293T cell line (Embryonic kidney cells) was generous gift 
from Prof.Susan Kidson laboratory.  All the cell lines, were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Highveld Biological (Pty) Ltd., RSA), supplemented with 10% 
(v/v) heat inactivated foetal bovine serum (Highveld Biological (Pty) Ltd., RSA), 100U/ml 
penicillin (P3032 Sigma, USA) and 100μg/ml streptomycin (S-91370 Sigma, USA), and 
incubated in 5% C02, 95% humidity at 37oC (See appendix A, B & C). 
2.2 . DACARBAZINE (DTIC) TREATMENT 
Dacarbazine (DTIC) was obtained from Sigma, South Africa (D2390). DTIC was diluted to a 
working stock of 10mM in NaCl (0.9%), from the original stock solution and stored as 
aliquots at -20 oC. From these aliquots, concentrations ranging from 0.480mM to 3mM were 
used and subsequently diluted in the cell culture medium, for each experiment. The final 
concentration of NaCl in all experiments remained equal or less than 0.9%. Human UCT-
Mel1 and A375 cells were seeded into 96-well tissue culture grade plates (Greiner 
CELLSTAR, South Africa) and allowed to adhere overnight at 37oC in a 5% C02 humidified 
incubator (MCO-175M, Sanyo). The following day, the medium was removed and the cells 
were exposed to DTIC concentrations of 0.480, 0.850, 1, 1.5 and 3mM, for a further 24 and 
48hours at 37oC. After the treatment, a cell viability assay was conducted to assess the 
cytotoxic effect of DTIC on the cells. 
2.3. CELL VIABILITY ASSAY 
Cell viability following DTIC treatment was monitored using the XTT assay according to 
manufacturer instructions (XTT Cell proliferation Kit II Cat. No 11465015001, Roche, 
Germany). Briefly, this was performed by adding XTT solution, four hours prior the end of 
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the 24 or 48 hours DTIC treatment period. In this assay metabolically active cells cleave the 
yellow tetrazolium salt, to form orange formazan crystals, which absorb light at 450nm and 
650nm (reference wavelength), using a spectrophotometer (Versamax, Molecular devices, 
South Africa), using softMax pro4.3.1 software. The absorbance values were normalized to 
the untreated control (vehicle) and results presented as percentage of cell viability. 
2.4. HYPERICIN 
Hypericin from the Hypericum perforatum species, (95% pure by high-performance liquid 
chromatography), was obtained from Sigma, South Africa (56690). A 2mM stock solution 
(Appendix D) was made in dimethyl sulfoxide (DMSO, Merck) and stored as aliquots at -
80°C. Working solutions were prepared fresh at a concentration of 50μM in phosphate-
buffered saline (1x PBS, Appendix E) and then diluted further directly in the complete cell 
culture medium containing fetal bovine serum (Appendix A& B). All experiments were 
carried out under subdued light conditions. 
2.5. LIGHT ACTIVATION 
Hypericin was activated with 5J/cm2 using green-yellow laser light (Fiber coupled laser 
nodule, 561nm, RGBlase LLC, California, USA). A light with fiber optic cable (561nm) was 
used to administer the dose. The power output was measured to 20mW using a portable 
power meter (FieldMate, Laser Power Meter). The following equation was used to obtain the 
time of exposure. 
 
2.6. HYPERICIN-PHOTODYNAMIC THERAPY (HYP-PDT) 
UCT-Mel1 and A375 cells were exposed to 4 hours of hypericin in complete media followed 
by a wash in, 1xPBS and light activation with 5 J/cm2 yellow-green laser in 1x PBS for all 
experiments. Following light activation, complete media was added to the cells. At different 





2.7. COMBINATION THERAPY: DACARBAZINE +HYP-PDT  
 UCT-Mel1 and A375 cells were seeded into 35mm dishes (Irradiated and unirradiated plates, 
having control/vehicle and treated wells), and left overnight at 37oC to adhere. The following 
day, the cells were treated with a DTIC concentration (1250µM) for 24 or 48hours. Four 
hours before the end of the DTIC treatment time points (i.e. 20 and 44h), the cells were 
exposed to 3µM hypericin for 4 hours, followed by two successive washes in 1x Phosphate 
buffer Saline (PBS). Upon completion of the HYP-PDT (performed in 1xPBS), which was 
performed at 20mW with a light intensity of 5J/Cm2, the 1xPBS was gently removed and new 
medium was replaced. The cells were then subjected to additional analyses. For each 
experiment cells were exposed to ten different treatments: 
o vehicle with no-irradiation (V-L) 
o vehicle with light-activation (V+L) 
o Control with no-irradiation (C-L) 
o Control with light-activation (C +L) 
o DTIC with no-irradiation (DTIC-L) 
o DTIC with light-activation (DTIC +L) 
o hypericin with no-irradiation (HYP-L) 
o hypericin with light-activation (HYP+L) 
o hypericin+DTIC with no-irradiation (HYP+DTIC-L) 









Figure 1: Experimental set up for combination therapy. Melanoma Cells were seeded and left to 
adhere to the dish overnight. The following day, the cells were exposed to DTIC (1.25µM) for 24 or 
48h. Thereafter, the cells were exposed to hypericin for 4 hours (prior the end of DTIC treatment) 
followed by light activation with 5J/cm2 at a power of 20mW (49seconds per well within the 96 well 
plate and 40min for each 35mm dish). Upon completion of the treatments, the cells were put in new 
medium and left for 24h recovery, before further analysis were performed. 
 
 
Figure 2: The different treatments of the combination therapy (DTIC+HYP-PDT). 
2.8. WESTERN BLOT ANALYSES: ATP-BINDING CASSETTE (ABC) 
TRANSPORTER PROTEIN EXPRESSION 
Western blot analysis is an indirect method used to detect proteins of interest by resolving the 
sample protein on polyacrylamide gels, followed by the electrophoretic transfer of the protein 
onto membranes. This is followed by detection using specific antibodies to the protein(s) of 
interest followed by enhanced chemiluminescence (ECL) detection (Thermo scientific, Prod# 
34080, USA) on an x-ray film (SANTA CRUZ biotechnology, catalog# sc-201697, USA) 
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For the preparation of cell lysates, UCT-Mel1 and A375 cells were grown to 70% confluency 
and treated with 1250µM DTIC alone or with combination therapy (DTIC+PDT). After the 
experimental period (24 hours), adherent cells were harvested and proteins were extracted on 
ice by adding complete radio-immunoprecipitation assay (RIPA) buffer (Appendix I&J) to 
the dish of cells. Cells were collected with a cell scraper and the lysed cells were then 
transferred to a 1.5 ml microfuge tube, vortexed and shaked on ice, for 30 min on the belly 
dancer (STOVALL, life science, inc, Greensboro, NC USA). Samples were then centrifuged 
at 12000 rpm at 4oC for 20 min. The supernatant was finally transferred to a clean 1.5 ml 
microfuge tube and stored at -80oC till further analyses were conducted. 
The protein concentration of the samples was determined using the Pierce BCA Protein 
Assay Kit (Thermo Scientific, USA). This kit is a colorimetric assay where a purple coloured 
reaction product is produced upon chelating reaction between two bicinchoninic acid 
molecules and one cuprous ion. This product is then read spectrophotometrically (Versamax 
Tunable microplate reader-molecular devices, South Africa) at 562 nm and compared to a 
standard curve generated using known concentrations of bovine serum albumin (BSA, 
Sigma-Aldrich, USA) . The protein concentration of each sample was then calculated using 
SoftMax Pro software (Version 4.3.1 Life Sciences Edition, USA). 
To analyse protein expression, identical amounts of proteins (30µg), were diluted in 5x 
loading dye, loaded into wells of stacking and resolving SDS-polyacrylamide gel (7.5/ 5%) 
and electrophoresed at  80V for 30min and 120 V for 1hour in 1x running buffer. The 
separated proteins were then transferred, at 100V for 1hour, onto a nitrocellulose membrane 
(Hybond ECL Amersham, RPN203D, GE Healthcare), in 1x transfer buffer. The blotted 
membrane was subsequently immersed in Ponceau-S and stained for total protein for 5min. 
The membrane was then briefly washed in water, and digitally scanned (CanoScan LiDE210, 
Canon). The membrane was doubly immersed in 1x TBS-T for 5min, before being blocked 
for 1hour at room temperature in 5% milk TBS-T. Upon blocking completion, the membrane 
was exposed to the primary antibodies (ABCB1/5 & ABCG2 (1:200), p38 (1:5000)) 
overnight at 4 oC. The following day, the membrane was washed (3x 10min) in 1x TBS-T 
and the secondary antibodies (Goat-anti mouse (1:1000)/ (1:3000) & donkey-anti Goat 
(1:4000)/ (1:3000) and Goat-anti rabbit (1:5000)) were added for 1hour at room temperature 
(see table 1) and exposed to SuperSignal West Pico chemiluminescent ECL detection reagent 
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for 1min. Finally for immunodetection, the X-ray film, was manually exposed to the 
membrane developed (G150, AGFA) and fixed (G354, AGFA) for viewing.  
 
2.9. MICROGRAPHY OF COMBINATION THERAPY 
(DACARBAZINE+HYP-PDT) 
UCT-Mel1 and A375 metastatic melanoma cells were seeded in 35 mm2 coverslips in 35mm2 
cell culture dishes (200 000) and treated according to the laser induced DTIC+HYP-PDT 
treatment protocol (see Figure 1), for 40min with light intensity of 5J/Cm2 at a power of 
20mW. Once the treatment was completed, the cell’s nucleus were stained for 30min, through 
addition of the nuclear Hoechst dye (33342/33258) (10mg/ml) to the medium at a dilution of 
1:5000. Upon completion of the nuclear staining, the medium was removed (DMEM++) and 
replaced with a serum free medium (DMEM). The cells were then viewed immediately with a 
fluorescent microscope (Carl Zeiss, Axiovert 200M, (Germany) at a magnification of 400X, 
using the coverslips. Images were recorded with appropriated digital software (AxioVision 
V.SPI) in the blue (Hoechst) and Cy3 (HYP) channels. Overlay pictures of these 2 channels, 
as well as their respective phase contrast images were also captured. Scale bars of 50µM 
were included on each picture.   
 
2.10. CLONOGENIC ASSAYS 
The clonogenic capacity of the UCT-Mel1 and A375 metastatic melanoma cells, upon 
combination (DTIC+HYP-PDT) and chemotherapeutic treatments was investigated. This was 
performed, by seeding melanoma cells into 6cm dishes and leaving them overnight at 370C 
for adherence. The following day, the cells were treated with DTIC alone or with 
combination therapy (DTIC + HYP-PDT) for 24 hour. Upon treatment completion, the cells 
were lifted using trypsin/EDTA (See appendix F), counted and re-plated to a lower density 
(400 cells per well) into 6 well plates. Once enough colonies were formed from the re-plated 
cells, medium was removed from each well. Then, the cell colonies were fixed with (3:1) 
methanol: acetic acid, for 15min per well after which  each well was stained with 0.5% 
crystal violet in methanol  for 15min, rinsed with ethanol and prepared for micrography. 
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Pictures were analysed using Image J software (version 1.43u; National Institutes of Health, 
USA). 
2.11.  STATISTICS 
Different statistical analyses were performed on the data obtained depending on the type     of 
experiment performed. For cell viability and colonogenic assay of UCT-Mel1 and A375 upon 
chemotherapy and combination therapy (DTIC+HYP-PDT), a 1way ANOVA and 
Bonferroni’s/Dunnett’s multiple comparisons post-test were applied to the results. However, 
for densitometry analysis of the western blot results and clonogenic assay, a T-test was 
performed. A P-values of <0.05 was considered to be of significance. All graphs and statistics 
were performed using GraphPad Prism (Version 5.01, USA). 
Table1: concentrations of primary and secondary antibodies used 
Primary antibody (in 
5% fat-free milk-TBS-
T) 
Conc. Secondary antibody Conc. 
ABCB5 (Cat: (N-
13):sc-104019, Goat 




Donkey anti-goat Horseradish 
peroxidase conjugated (Cat: sc-2020, 
Santa Cruz Biotechnology,USA) 









Goat anti-mouse Horseradish 
peroxidase conjugate (Cat: 170-6516, 
BioRad Laboratories,USA) 









Goat anti-mouse Horseradish 
peroxidase conjugate (Cat: 170-6516, 
BioRad Laboratories,USA) 
1:3000 in 5% fat-
free milk-TBS-T 
p38 (Cat: p-38 MAP 





Goat anti-rabbit Horseradish 
peroxidase conjugate (Cat: 170-6515, 
BioRad Laboratories,USA) 




Chapter 3: Results                                                             
3.1. CELL VIABILITY OF HUMAN METASTATIC MELANOMA 
FOLLOWING DACARBAZINE TREATMENT (24 AND 48 
HOURS) 
Investigating the possible synergistic action of chemotherapy (DTIC) and hypericin activated 
photodynamic therapy (HYP-PDT) in resistant melanoma skin cancer was the central aim 
of this project. In order to realise it, the lethal dose of the chemotherapeutic drug DTIC 
killing 50% of metastatic melanoma cells (LD50), had to be established before combining it 
with HYP-PDT. As displayed in figure 6, both pigmented (UCT-Mel1, Figure 6A) and 
unpigmented (A375, Figure 6B) metastatic melanoma were treated with increasing DTIC 
concentrations ranging from 0.48 to 3mM. After 24 hour treatment, cell viability, which was 
normalised to the vehicle control (0.9% NaCl), revealed that none of the DTIC concentrations 
were cytotoxic to the pigmented UCT-Mel1 melanoma (Figure 6A). In contrast, 1.5mM 
DTIC significantly reduced the viability of the A375 melanoma cells but this decrease was 
only 20% less than the control (Figure 6B). Unexpectedly, 3mM had no effect on the viability 
of A375 melanoma cells. These results prompted the extension of the DTIC treatment for an 





Figure 6: Cell viability 24 hours post DTIC treatment of pigmented (UCT-Mel1) and 
unpigmented (A375) human metastatic melanoma cell lines. UCT-Mel1 (A) and A375 (B) 
melanoma cells were treated with various DTIC concentrations (0.48; 0.85; 1; 1.5 and 3mM) for 24 
hours. Following treatment, cell viability was analyzed using the XTT assay. Results were presented 
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as percentage of cell viability normalized to the 0.9% NaCl control. Significant difference = P *< 
0.05. Statistical analysis used 1way ANOVA and Dunnett’s multiple comparison test; n=3). 
Upon completion of the 48hour DTIC treatment, a significant 22.3% reduction in cell 
viability could be seen in the UCT-Mel1 (pigmented) melanoma cell line treated with 1.5mM 
DTIC (Figure 7A). Interestingly, in the unpigmented A375 (unpigmented) melanoma, a 
significant dose-dependent decreased in cell viability could be observed for all the tested 
concentrations resulting in an LD50 of 1.25mM (figure 7B). These results suggested that 
UCT-Mel1 (pigmented) was more resistant to the DTIC treatment, when compared to the 






Figure 7: Cell viability 48 hours post DTIC treatment of pigmented (UCT-Mel1) and 
unpigmented (A375) human metastatic melanoma cell lines. UCT-Mel1 (A) and A375 (B) 
melanoma cells were treated with various DTIC concentrations (0.48; 0.85; 1; 1.5 and 3mM) for 48 
hours. Following treatment, cell viability was analyzed using the XTT assay. Results were presented 
as percentage of cell viability normalized to the 0.9% NaCl control. Significant difference = P *< 





3.2. CELL VIABILITY OF HUMAN METASTATIC MELANOMA 
FOLLOWING COMBINATION THERAPY TREATMENT 
(DTIC+HYP-PDT) AT 24 AND 48 HOURS 
Recent work in our lab showed that 3µM activated HYP-PDT was lethal to both pigmented 
(UCT-Mel1) and unpigmented (A375) metastatic melanoma cell lines 24hours post-
treatment. Hence, this concentration of HYP was then used in combination with the DTIC 
lethal dose causing fifty percent decrease in unpigmented melanoma cell viability (LD50, 
1250µM).  
As depicted in figure 8A (DTIC+L), the UCT-Mel1 cells displayed an expected 3.6% 
decrease in cell viability upon exposure to DTIC. Interestingly, a significant reduction of 
50.19% occurred with activated hypericin-PDT (Fig 8A, HYP+L). Despite the combination 
therapy (Fig 8A, DTIC+HYP+L) causing a reduction of 61.26% in the UCT-Mel1’s, this was 
not significantly different to the HYP-PDT alone (HYP+L). This suggested no additive 
combinatorial effect in the pigmented melanomas at 24hours. At the 48h time point (Fig 8B) 
however, the picture was quite different with the combination therapy (Fig 8B, 
DTIC+HYP+L) reflecting a significant difference (DTIC+L vs DTIC+HYP+L, p<0.001) 
between the chemotherapy alone and the combination treatment. This result suggests that a 
later time point enhances the combination efficacy (77.75% reduction in cell viability Fig 8B, 
DTIC+HYP+L) in highly resistant pigmented melanomas. Taken all together, these 
experiments had shown that HYP-PDT (Hypericin activated photodynamic therapy) and 
DTIC+HYP+L (combination therapy), were definitely overcoming the resistance observed 
after chemotherapeutic (DTIC) treatment at 24hours. Moreover, it also showed that the 
cytotoxicity observed within the DTIC+HYP+L was not a result of synergism, as this was not 








Analysis from the A375 treated group have shown that, depending on the respective therapy 
used i.e. chemotherapy and/or PDT, there was a  decrease in cell viability characterised by a 
reduction of 25% (DTIC), 55.1% (HYP+L) and 65.7% (DTIC+HYP+L) when compared to 
their vehicle control (0.9% NaCl + 0.15% DMSO) (Figure 9A). Although, HYP+L and 
DTIC+HYP+L were significantly different to their control (Figure 9A, P<0.0001), they were 
not significantly different to each other. However, (HYP+L and DTIC+HYP+L) were 
significantly different to the DTIC treatment only (Figure 9A, P<0.05 & P<0.0001). At 48 
hours (Figure 9B), a decrease in cell viability could be observed within the irradiated group 
(Figure 9B). The reduction was characterised by 50, 66 and 83.2% reduction in cell viability 
for DTIC+L, HYP+L and DTIC+HYP+L treatment, respectively (Figure 9B). However, 
significant differences were only obtained with DTIC+L, compared to the DTIC+HYP+L 
treatment (Figure 9B, P<0.001). Activated HYP (Figure 9B, HYP+L) showed no significant 
difference to the combination treatment (DTIC+HYP+L). Moreover, a reduction in cell 
viability could be seen, when the untreated A375 melanoma cells were compared to their 
vehicle control (Figure 9B, V+L). However, after 48h of treatment in the unirradiated group 
(Figure 9C), all the treated groups showed a significant reduction in cell viability (50, 18.4 






Figure 8: Cell viability 24 and 48 hours post combination therapy using 1250µM DTIC and 
3µM HYP-PDT on UCT-Mel1 (pigmented) human metastatic melanoma cells. UCT-Mel1 cells 
that were sequentially exposed to DTIC and irradiated with HYP (exposed to laser light) at 24 and 
48hour (A) and (B). Statistical difference = * < 0.05, **<0.001 and ***<0.0001. Statistics was 





emphasises that a longer period of exposure leads to a more potent effect even in the absence 
of light activation. In conclusion it could be deduced that PDT, chemotherapy (DTIC) and the 
combination thereof are more efficient at killing A375 unpigmented melanoma cells, as 




Figure 9: Cell viability 24 and 48 hours post combination therapy using 1250µM DTIC and 
3µM HYP-PDT on A375 (unpigmented) human metastatic melanoma cells. A375 cells that were 
sequentially exposed to DTIC and  irradiated with HYP (exposed to laser light) at 24 and 48hour (A) 







performed using the XTT assay and data was normalized to the 0.9% NaCl control. (Statistical 
difference = * < 0.05, **<0.001 and ***<0.0001. Statistics was analysed using a 1 Way ANOVA and 
Bonferroni’s multiple comparison test. n=3). 
 
3.3. METASTATIC MELANOMA CELL MORPHOLOGY 24 HOURS 
POST THERAPEUTIC TREATMENTS 
Following the determination of the cytotoxicity of the different treatments on the melanoma 
cells, the next objective was to investigate the morphological changes associated with these 
therapies 24 hours post-treatment.  
As displayed by the phase contrast image (Figure 10A) untreated A375 melanoma cell lines 
displayed a non-dendritic triangular, cobblestone-like morphology, upon confluence. 
However, when A375 cell lines were treated with DTIC for 24hours an alteration in cell 
morphology was observed. The treated cells now displayed irregular cell borders, with 
enlargement of their cytoplasm and a distinct flattening of the cells, gradually losing the 





Figure 10: Phase contrast images of unpigmented A375 melanoma cells (A) and dacarbazine 
(DTIC) treated A375 cells (B). A375 cells were cultured and treated with 1250 µM DTIC for 





Moreover, an increase in cell size could be observed with cells exposed to inactivated 
hypericin (HYP-L) for 24 hours. A number of these cells also displayed irregular membrane 
borders (Figure 11A, arrows). The DTIC+HYP combination treatment further resulted in a 
swelling of the cells accompanied with cellular rounding up, irregular cytoplasm and 







Figure 11:  Phase contrast images of unpigmented A375 melanoma cells; 24hour post- 
inactivated hypericin (HYP-L) (A) and combination therapy treatment (DTIC+HYP-L) (B). 
A375 cells were either exposed to HYP only or to DTIC+HYP-L for 24 hour. Images were captured 









Starkly, both HYP-PDT and DTIC+HYP+L treatment resulted in cell size reduction, cell 
swelling and pronounced vacuolisation in the cytoplasm with increased granularity and cell 
shrinkage (Figure 12A & 12B). 
 
 
From the fluorescent images, the control cells displayed an intact round Hoechst positively; 
stained nucleus, which could be seen within the untreated A375 cells (Figure 13A). However, 
after HYP+L and DTIC+HYP+L treatments, the nuclei appeared smaller with formation of 
nuclear aggregates within the nucleus (Figure 14A & 14B, arrows). Finally, cytoplasmic 
localisation of hypericin (intracellular red colour, HYP, Figure 14 & 15) could be seen as a 
specific perinuclear aggregation represented by red punctae (Fig 14 & 15, arrows) in all A375 
HYP- treated cells. 
 
Figure 12: Phase contrast images of unpigmented A375 melanoma cells; 24 hours post-hypericin 
induced photodynamic therapy (HYP+L) (A) and combination induced photodynamic therapy 
(DTIC+HYP+L) treatment (B). A375 cells were cultured and sequentially exposed to 1250µM 
DTIC and 3µM HYP, for 24 hour.  Images were captured 24 hour post-treatment. Magnification: 












Figure 13: Fluorescent images of Hoechst stained nuclei (Blue) of unpigmented A375 melanoma 
cells (A) and dacarbazine A375 treated cells (B). A375 cells were cultured and exposed to 1250µM 
DTIC for 24 hour. Images of Hoechst stained A375 cells, were captured 24 hours post-treatment. 






Figure 14: Fluorescent images of Hoechst stained nuclei (Blue) and hypericin (red) of 
unpigmented A375 melanoma cells; 24 hours post-hypericin induced photodynamic therapy 
(HYP+L) (A) and  combination therapy treatment (DTIC+HYP+L) (B). A375 cells were cultured 
and sequentially exposed to 1250µM DTIC and 3µM HYP for 24 hour. Images of Hoechst and HYP 
stained A375 cells, were captured 24 hour post-treatment (arrow: nuclear aggregate). Magnification: 









Figure 15: Fluorescent images of Hoechst stained nuclei (Blue) and hypericin (Red) of 
unpigmented melanoma cells treated with hypericin (HYP-L) (A) and combination treatment 
(DTIC+HYP-L). A375 cells were exposed sequentially to DTIC 1250µM and 3µM HYP for 24 hour. 
Images of Hoechst and HYP stained A375 cells, were captured 24 hour post-treatment (arrow: nuclear 












Control pigmented, UCT Mel1 cells exhibited a bipolar, dendritic morphology (Figure 16A). 
The DTIC and HYP-L treatments, resulted in an increased granularity and concomitant 
decreased dendricity (HYP treated group) when compared to their untreated controls (Figure 
16 B & 17 A). Interestingly, DTIC+HYP-L treatment resulted in complete dendritic loss and 







Figure 16: Phase contrast images of pigmented UCT-Mel1 melanoma cells (A) and dacarbazine 
treated UCT-Mel1 cells (B). UCT-Mel1 cells were cultured and exposed to 1250µM DTIC for 24 


















Figure 17: Phase contrast images of pigmented UCT-Mel1 melanoma cells; 24 hours post 
hypericin (HYP-L) (A) and combination therapy treatment (DTIC+HYP-L) (B). UCT-Mel1 cells 
were cultured and either exposed to 3µM HYP only or sequentially to 1250µM DTIC and HYP for 
24hour. Images were captured 24 hour post-treatment (Loss of dendrites). Magnification: 400x; Scale 













In addition, HYP+L and DTIC+HYP+L caused a drastic change in morphological features of 
UCT Mel1, with complete disruption of their cellular morphology with associated 







Figure 18: Phase contrast images of pigmented UCT-Mel1 melanoma cells; 24 hours post 
hypericin induced photodynamic therapy (HYP+L) (A) and combination therapy treatment 
(DTIC+HYP+L) (B). UCT-Mel1 cells were cultured and either exposed to HYP+L or sequentially to 
1250µM DTIC and 3µM HYP (DTIC+HYP+L) for 24 hour. Images were captured 24 hour post-
treatment (arrow: damaged and multi-dendritic cells). Magnification: 400x; Scale bar = 50µM. 
In contrast, fluorescent images, displayed a conservation of nuclear integrity after all 
treatments (Figure 19, 20 and 21).  Finally, a cytoplasmic and perinuclear localization of 
HYP (red colour in Figure 20 and 21) occurred around the nucleus in contrast to the red 
punctate pattern of localization in the A375s (Figure 20 & 21). From these observations, 
difference in cell morphology between pigmented (UCT-Mel1) and unpigmented melanoma 
(A375) could be seen, following HYP+L and DTIC+HYP+L particularly (Figure 12 & 18). 
This was of particular interest, as difference in nuclear integrity could be reflective of the  
sensitivity (or mode of cell death) of the different melanoma cell lines to the respective 










Figure 19:  Fluorescent images of Hoechst stained nuclei (Blue) of pigmented UCT-Mel1 
melanoma cells (A) and dacarbazine treated UCT-Mel1 cells (B). UCT-Mel1 cells were cultured 
and exposed to 1250µM DTIC for 24 hour. Images of Hoechst stained UCT-Mel1 cells, were 






Figure 20: Fluorescent images of Hoechst stained (Blue) and hypericin (Red); 24 hour post-
Hypericin (HYP-L) (A) and combination therapy (DTIC+HYP-L). UCT-Mel1 cells were cultured 
and either exposed to 3µM HYP only or sequentially to 1250µM DTIC and HYP for 24hour. Images 
were captured 24 hour post-treatment. Images of Hoechst and HYP stained UCT-Mel1 cells, were 











Figure 21: Fluorescent images of Hoechst stained nuclei (Blue) and hypericin (red) of pigmented 
UCT-Mel1 melanoma cells; 24 hours post-hypericin induced photodynamic therapy (HYP+L) 
(A) and  combination therapy treatment (DTIC+HYP+L) B). UCT-Mel1 cells were cultured and 
sequentially exposed to 1250µM DTIC and 3µM HYP for 24 hour. Images of Hoechst and HYP 
stained UCT-Mel1 cells, were captured 24 hour post-treatment. Magnification: 400x; Scale bar = 
50µM. 
 
3.4. ASSESSMENT OF METASTATIC MELANOMA CLONOGENIC 
ACTIVITY 24HOURS POST-THERAPEUTIC TREATMENTS 
As clonogenicity is a marker of tumorigenicity, the next objective was to determine the 
clonogenic capacity of the pigmented (UCT-Mel1) and unpigmented (A375) metastatic 
melanoma, 24 hours post-therapeutic treatments. As shown in Figure 22, 24h DTIC treatment 
was successful at significantly reducing the clonogenic activity of the A375 (unpigmented) 
melanoma cell lines, when compared to their control (Figure 22A). In contrast, the pigmented 
melanoma cells (UCT-Mel1) maintained their clonogenic activity despite DTIC treatment, 
(Figure 22B). Although upon DTIC treatment UCT-Mel1 cells were more clonogenic than 
the A375, they formed five times less colonies as compared to the A375 cells upon 7 days 
treatment (Figure 22). These observations clearly, re-enforced the resistance of UCT-Mel1 to 
the DTIC treatment (when compared to the A375), which nicely correlate with the cell 
viability, following DTIC treatment in Figure 6 & 7. Upon establishment of the two 
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metastatic melanoma cell lines clonogenic activity upon DTIC treatment, the next aim was to 





Figure 22:  Clonogenic activity of pigmented (UCT-Mel1) and unpigmented melanoma (A375), 
24 hours post DTIC treatment. A375 (A) and UCT-Mel1 melanoma cells (B) were exposed to 
1250µM DTIC for 24 hours and re-plated post treatment at a lower density for clonogenic capacity 
assessment. Results are presented as numbers of colonies. (Significant difference = P *< 0.05. 






To assess the efficacy of the combination treatment, the clonogenic activities were analyzed 
after 24hours DTIC+HYP+L. Figures 23 and 24 show that both HYP+L and DTIC+HYP+L 
resulted in complete abrogation of the clonogenic activity in UCT-Mel1 and A375 melanoma 
cell lines, 24 hours post-treatment compared to their respective controls. Interestingly, the 
UCT-Mel1 displayed a 46.25% reduction in colony number compared to the 53% reduction 
in the A375 cells, following DTIC+HYP-L treatment, clearly illustrating the increased 
resistance/tumorigenicity of the pigmented melanomas (Figure 23 & 24).  Due to the 
differential clonogenic activity observed, in response to the different therapeutic treatments 
on UCT-Mel1 and A375 melanoma cells, our next objective set to investigate the possible 





Figure 23: Clonogenic activity of pigmented metastatic melanoma (UCT-Mel1), 24 hours post 
combination therapy (DTIC+HYP-PDT) treatment. UCT-Mel1melanoma cells were sequentially exposed 
to DTIC and HYP-PDT for 24 hours. 24 hours post-treatment completion, UCT-Mel1 cells were re-plated at 
a lower density for clonogenic capacity assessment. Results were presented as numbers of colonies. 





Figure 24: Clonogenic activity of unpigmented metastatic melanoma (A375), 24 hours post 
combination therapy (DTIC+HYP-PDT) treatment. A375 melanoma cells were sequentially 
exposed to 1250µM DTIC and HYP-PDT for 24hours. 24 hours post-treatment completion, A375 
cells were re-plated at a lower density for clonogenic capacity assessment. Results were presented as 
numbers of colonies. (Significant difference = P *< 0.05. Statistical analysis T-test; n=2). 
 
3.5. ABC TRANSPORTER PROTEIN EXPRESSION FOLLOWING 
THERAPEUTIC TREATMENTS 
It is well documented that ABC transporters are involved in therapeutic treatment failure by 
lowering the accumulation of therapeutic drugs within cancer cells13,22,93,106. With this in 
mind, the next set of experiments aimed to establish ABC transporter protein expression 
before and after therapeutic treatments, to establish their possible contribution to therapy 
resistance in the melanoma cells. 
Figures 25 and 26 clearly revealed that ABCG2 transporter expression was increased upon 
DTIC treatment (24hours) in both the A375 and UCT-Mel1 cells compared to their untreated 
controls. Interestingly, none of these increased expressions (ABCG2) showed significance 









Figure 25: ABCG2 protein expression in unpigmented metastatic melanoma cells (A375), 24 
hours post Dacarbazine (DTIC) treatment: Western blot of ABCG2 protein expression in 293T 
cells (positive control, human embryonic kidney cells), C (untreated control) and dacarbazine (DTIC) 
treatment (24 hours) (A). Densitometry analysis showing the optical density (fold) of ABCG2 
transporters, 24 hours post DTIC treatment. Data was normalized to the control, by obtaining the ratio 
of ABCG2 expression (band optical density) and its loading control, p38 (B). No statistical 

























Figure 26: ABCG2 protein expression in pigmented metastatic melanoma cells (UCT-Mel1), 24 
hours post Dacarbazine (DTIC) treatment: Western blot of ABCG2 protein expression in 293T 
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cells (positive control, human embryonic kidney cells), C (untreated control) and dacarbazine (DTIC) 
treatment (24 hours) (A). Densitometry analysis, showing the optical density (fold) of ABCG2 
transporters, 24 hours post DTIC treatment. Data was normalized to the control, by obtaining the ratio 
of ABCG2 expression (band optical density) and its loading control, p38 (B). No statistical 
significance was obtained using the student t-test (*P<0.05) (n=2).  
Assessment of ABCB1 (also called multidrug resistance protein (MDR)) protein expression 
displayed an increase upon 24h DTIC treatment in UCT-Mel1 (during optimization where all 
the melanoma cells were collected), when compared to the control (Figure 27A). However, it 
should be noted that these cells represented all the cells and was not restricted to a resistant 
population. However, this was not reproducible upon additional experimental repeats in 
UCT-Mel1, as well as A375 melanoma cell lines (Figure 27B & 28). In future further 
experiments should involve harvesting of the total treated cell population (adherent and 










Figure 27: ABCB1 (MDR1) protein expression in pigmented metastatic melanoma cells (UCT-
Mel1), 24 hours post Dacarbazine (DTIC) treatment: Western blot of ABCB1 protein expression 
in HeLa cells (positive control, human cervical  cancer cells), C (untreated control) and dacarbazine 
(DTIC) treatment (24 hours) during optimization (A) and experimental repeat (B).  Results of ABCB1 





Figure 28: ABCB1 (MDR1) protein expression in unpigmented metastatic melanoma cells 
(A375), 24 hours post Dacarbazine (DTIC) treatment: Western blot of ABCB1 protein expression 
in HeLa cells (positive control, human liver  cancer cells), C (untreated control) and dacarbazine 
(DTIC) treatment (24 hours).  Results of ABCB1 expression was normalised to the loading control 
p38 (38KDa). 
Moreover, detection of the ABCB5 expression, which is specifically overexpressed in 
melanoma upon chemotherapy treatment13, was observed upon DTIC treatment and control 
cells (Figure 29). Finally, no ABCG2 expression was detected in the two melanoma cell lines 





Figure 29:  ABCB5 protein expression in pigmented metastatic melanoma cells (UCT-Mel1), 24 
hours post Dacarbazine (DTIC) treatment: Western blot of optimized ABCB5 protein expression in 
pigmented melanoma cells, C (untreated control) and dacarbazine (DTIC) treatment (24 hours) (A).  






Figure 30: ABCG2 protein expression in pigmented (UCT-Mel1) and unpigmented (A375) 
metastatic melanoma cells (UCT-Mel1), 24 hours post-combination therapy treatment: Western 
blot of ABCG2 protein expression in 293T cells (positive control, human embryonic kidney cells), C 
(untreated control) and dacarbazine (DTIC) treatment (24 hours) in UCT-Mel1 (A) and A375 (B). 
Data was normalized to the control, by obtaining the ratio of ABCG2 expression (band optical 









Chapter 4: Discussion 
Despite extensive research and clinical trials, the prognosis and survival of metastatic 
melanoma remains dismal. Early detection of localized melanoma may be cured through 
surgery however there is no therapy for metastatic melanoma or melanoma with metastatic 
potential. In addition, recurrence rates of resected melanoma remain high. Because melanoma 
is inherently resistant to traditional forms of chemotherapy and radiotherapy 1, various 
strategies have been developed for treatments which include immunotherapy eg. Interleukin-
2 (IL-2) 2, radiotherapy 3 biochemotherapy 4-7 and gene therapy 2, 8, the application of 
newer therapies are pertinent. Photodynamic therapy (PDT) is one such therapy. More 
recently, cocktails and combination therapies have been introduced in an attempt to not only 
eradicate the melanoma tumorigenic cells abut also reduce the resistance of the remaining 
cancer cells. With this in mind, the central aim of this project was, through combination of 
chemotherapy (DTIC) and HYP-PDT, to investigate their possible synergistic action in 
melanoma skin cancer. This was rendered possible by firstly determining the lethal dose of 
DTIC killing 50% of the melanoma cells (UCT-Mel1 and A375). Treatment (24 hour) of the 
pigmented (UCT-Mel1) (Figure 6A) and unpigmented (A375) melanoma cells, with 
increasing DTIC concentrations (0.48-3 mM) displayed cytotoxicity towards the A375 cells 
only (Figure 6B). However, when the treatment was prolonged for an additional 24 hours 
(48hour treatment in total), a reduction in cell viability of the pigmented UCT-Mel1 cells 
(22.3%) could be observed at1.5mM DTIC treatment (Figure 7A). The equivalent dose at this 
time point in the A375 cells led to a 54.64% cell viability (Figure 7B). These results suggest 
that pigmented melanoma (UCT-Mel1) is more resistant to chemotherapeutic treatment 
(DTIC), compared to unpigmented melanoma. This observed resistance in the pigmented 
cells is not that unexpected as both our earlier work27,47 attribute resistance in pigmented cells 
to the presence of melanin acting as an antioxidant to neutralize ROS and melanosomes 
acting as a “sink” to “mop up” chemotherapeutic drugs, leading to treatment failure. 
Interestingly though, in this scenario, it seems that the presence of melanin is the greater 
resistant mechanism as A375 cells have functional melanosomes present in their cytoplasm, 
they are just devoid of melanin. 
 As previous work in our lab had determined 3µM Hypericin (3µM HYP) to be lethal to 
UCT-Mel1 and A375 melanoma cells 24 hour post-treatment 46, this concentration was used 
in combination with our DTIC lethal dose (1250µM) to investigate cell resistance  
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 Twenty four hour treatment analyses of the UCT-Mel1 cell viability (Figure 8A) revealed 
that the DTIC exposed to light (DTIC+L) was not lethal to the cells (3.6% reduction). 
However, when the cells were treated with activated hypericin (HYP+L) or the combination 
treatment (DTIC+HYP+L) a significant reduction in cell viability was obtained (50.19% & 
61.26%, respectively). This lethal effect (DTIC+HYP+L, Figure 8B), was further pronounced 
upon 48 hour treatment of the UCT-Mel1 cells with a resultant reduction of 77.75% in cell 
viability. However, this was not a result of synergism between the HYP+L and 
DTIC+HYP+L, as no significant difference was obtained between the two. In comparison to 
the UCT-Mel1 cells, treatment of A375 cells at both time points (24 & 48 hour) resulted in a 
better therapeutic outcome, respectively causing 25% (DTIC+L), 55.1% (HYP+L) and 65.7% 
(DTIC+HYP+L) reduction in cell viability at 24 hour (Figure 9A) and a further 50, 66 and 
83.2% cell viabilities at 48 hour after treatment (Figure 9B). Taken together these results 
showed that UCT-Mel1 were still more resistant to the therapeutic treatment, when compared 
to the A375 cells. Previous results in our laboratory strengthen the postulate that 
pigmentation may play a role in resistance of these melanoma cells to PDT. However, to be 
sure of this theory, future work directed at the chemosensitivity will have to involve 
experiments in an identical cell line that is more or less pigmented. Interestingly, 
corroborating recent work showed not only that hypericin localized in melanosomes, but also 
but that the melanosomes were involved in the eradication of drugs entering melanocytic 
cells47,42,60.  
Once the cytotoxic profile of the chemotherapeutic (DTIC) and combination therapy 
treatments were acquired, the next objective was to analyses the morphological changes 
associated with the cellular response to these treatments. Morphologically, the HYP+L and 
DTIC+HYP+L treatments revealed complete disruption in cellular morphology associated 
with increased vacuolization in A375 and cytoplasmic shrinkage in UCT-Mel1 melanoma 
cells. In addition,  cell shrinkage was observed in both cell lines, this  with increased in 
granularity and cell swelling in A375, as opposed to the UCT-Mel1, where cells with 
multiple morphology (Flattened, multiple narrow dendrites) were depicted (Figure 12 and 
18). These cell dependent morphological changes were further amplified through the 
fluorescent images, displaying different HYP distribution and nuclear integrity resulting from 
the treatments in both cell lines (Figure 14 and 21). This was characterized by specific 
punctate, perinuclear aggregation of the HYP in A375, as opposed to a homogenous 
distribution of HYP around the nucleus in UCT-Mel1 (Figure 14 and 21). Although 
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cytoplasmic localization of HYP was observed in both cell lines, difference in nuclear 
integrity was detected. In the A375 cells, formation of small nuclear aggregates was 
observed, when compared to the UCT-Mel1 where nuclear integrity was conserved (Figure 
14 and 21). These morphological differences in the two melanoma cell lines, could suggest 
different modes of cell death. According to Davids et al. (2008) and Kleeman et al. (2014), 
HYP-PDT induces a necrotic mode of cell death in the UCT-Mel1, while activating an 
apoptotic mode of cell death in A375 cells46,42. Similarly, the increased vacuolization 
observed in A375 could be indicating an apoptotic mode of cell death. However, increased 
vacuolization could also be evidence of autophagy and a resultant attempt of the cells to resist 
the treatment. It is more plausible that these cells are dying by apoptosis as Kleeman et al. 
(2014), showed HYP to  co-localize in lysosomes, endoplasmic reticulum (ER), mitochondria 
and melanosomes of these cells with a resultant extrinsic (A375 cells) and intrinsic (UCT-
Mel1) caspase-dependent mode of cell death42. Further analyses would be needed to delineate 
these differences. The complete morphological disruption depicted in UCT-Mel1 upon 
treatments (HYP+L and DTIC+HYP+L) is clear evidence of necrosis.  
Clonogenic analyses are reflective of the tumorigenicity of cancer cells. The premise is that 
the more clonal the cells, the more likely they are to form tumors. Our analyses revealed that 
exposure of the two melanoma cell lines to hypericin (HYP-L), DTIC only and the 
combination without light activation (DTIC+HYP-L) showed that the A375 cells were more 
sensitive i.e. created less colonies compared to the UCT-Mel1 (Figure 22, 23 and 24). The 
resistance observed in UCT-Mel1, upon DTIC and DTIC+HYP-L treatment correlated with 
its cell viability results (Figure 6, 7, 8 and 9) and could possibly be  related to the 
development of a side population having stem cells properties111. These side stem cell like 
population cells are therapeutically resistant cells (different from the main resistant 
population), slow cycling cells, found to overexpress specific ABC transporter proteins 
(ABCB5 and ABCB1), grow under hypoxic conditions and re-form the parental tumor 
causing the clinically observed relapse 10,82, 93, 119, 120, 110. In contrast, exposure of the two 
melanoma cell lines to treatment (HYP+L and DTIC+HYP+L) resulted in complete 
abrogation of their clonogenic activities (Figure 23 and 24).  This would imply that the 
treatment, with HYP+L only or in combination completely destroys the side population cells, 
making it a potentially effective treatment option. 
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As this side population confers resistance, and the fact that this resistance may be due to 
increased ABC transporter expression, our next objective was to determine the ABC 
transporter (ABCB1, ABCB5 and ABCG2) protein expression before and after DTIC and 
combination therapy treatment. 
In cancer, ABC transporters have been implicated in resistance to therapeutic treatments, by 
lowering the intracellular accumulation of cytotoxic drugs, below their cytotoxic threshold,3, 
22,193. Although the expression of these transporters are said to be specific in response to the 
exposure of certain cytotoxic drugs, the overall expression is varied with respect to types of 
treatments and cancers treated. These transporter expressions are often related to functional 
requirements of the cell. For example, ABCG2, also known as the breast cancer resistant 
protein (BCRP) has been involved in resistance to cytotoxic drugs 105,106,  121. For this reason, 
we concentrated on the expression levels of ABCB1/MDR, ABCB5 and ABCG2/BCRP. Our 
results showed that ABCG2 expression was increased after 24 hour DTIC treatment only in 
both the A375 and UCT-Mel1 cells. The expression in the A375 cells corroborated recent 
work of Wu et al. (2013), who showed that overexpression of ABCG2 in A375 melanoma 
cells, resulted in vemurafenib chemotherapeutic treatment failure102. Furthermore in the same 
cell type (A375), Goler-Baron et al. (2012) showed that photodestruction of ABCG2 rich 
extracellular vesicles (sequestering chemotherapeutic drugs, imidazoacridinones and 
topotecan) sensitized the cells to therapeutic treatment. To our knowledge, no reports thus far 
have highlighted the increase in expression of the ABCG2 transporters in pigmented 
melanoma cells. It is clear from our results and the literature that increased ABCG2 
expression is a direct result of cell exposure to chemotherapeutic drugs. The results of this 
study however, further emphasize that this increased expression is chemo-specific and that 
the presence of melanin (UCT-Mel1) has no effect in increasing resistance and/or decreasing 
the expression of ABCG2.  
Having established the expression of ABCG2 in both UCT-Mel1 and A375 cells upon DTIC 
treatment (24hour), we next attempted to determine its expression using the combination 
therapy (DTIC+HYP-L, DTIC+HYP+L, HYP-L and HYP+L). Our results showed that upon 
combination therapy treatment, no detection of ABCG2 protein expression in either the UCT-
Mel1 or A375 cells. Unfortunately, this seemed to be related to the quality of the antibody, as 
no expression could be detected in the positive control 293T cells. Numerous attempts at 
optimizing further antibody concentrations and conditions resulted in no better results.  
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The ABCB1 transporter expression is related to multi-drug resistance protein (MDR), which 
is involved in resistance to chemotherapy93,122,123. Analysis of the ABCB1 transporter 
expression in our system initially revealed an increased expression upon 24 hour DTIC 
treatment (see Figure 27A). However, despite numerous repeated attempts, no detection of 
the transporter (ABCB1) could be obtained in either the UCT-Mel1or A375 cells (Figure 27B 
and 28). Two plausible reasons for this could be related to the percentage of the resistant 
population and ii) that only adherent cells were harvested for ABCB1 protein detection. 
According to the literature, the melanoma resistant populations overexpressing the ABC 
transporters (ABCB1, 5 and ABCG2) represent between 0.1 to 5% of the total tumor 
populations110,124,94. Knowing that only the adherent cells were harvested for ABC 
transporters protein expression, this could have resulted in a dilution of the melanoma cells 
fraction overexpressing these proteins. The possibility of it being due to an antibody detection 
issue was ruled out as detection of this transporter in positive control (Hela cells) cells 
displayed positivity (Figure 27B & 28). In future, further experiments should involve 
harvesting of the total treated cell population (adherent and floating cells). Despite the fact 
that this experiment was not reproducible, the increased detection level upon DTIC treatment 
would suggest that UCT-Mel1 may partly develop resistance to DTIC, by overexpressing the 
ABCB1, as has been reported in A375 melanoma cells and other cancers 93,94.  
Finally, we analyzed ABCB5 expression, which is involved in melanoma resistance to DTIC 
chemotherapy13. Our results of both pre and post DTIC treatment showed that both control 
and DTIC treated UCT-Mel1 cells expressed ABCB5 (Figure 29). However, as in the case of 
the ABCB1 transporter results, no definitive expression levels could be detected which we 
suspect could be due to the fact that only the adherent cell population was harvested. A 
limitation to this result was certainly the lack of a positive control i.e. cells overexpressing 
ABCB5. A future attempt to confirm the expression of ABCB5 could involve transfection of 
any cell line with a plasmid containing the ABCB5 gene. Thus, to our knowledge, no positive 
control for ABCB5 exists currently. However assessment of the ABCB1 and ABCB5 
expression were not performed, due to the detection problems encountered upon 
chemotherapy treatment. 
Overall, these results demonstrated that melanoma resistance to chemo and combination 
phototherapies are dependent on the pigmented phenotype and possibly their expression of 
the ABC transporters within the cells. This was reflected by the UCT Mel1 resistant to 
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chemotherapy and combination therapy when compared to their unpigmented counterpart. 
This correlated with the clonogenic activity upon chemotherapeutic treatment. Interestingly, 
the combination therapy concomitantly abrogated the resistant phenotypes in both cell lines. 
This observation matched the morphological differences obtained after treatment in both cell 
types. Furthermore, these observed resistance features were shown to correlate with increased 
ABCG2 protein expression. However, expressions of ABCB1 and ABCB5 in response to 
DTIC treatment were inconclusive. 
4.1. FUTURE RESEARCH 
Although a number of novel conclusions have been drawn from this work, to strengthen the 
research even further, several points could be included. These are: 
- Further experiments should involve harvesting of the total treated cell population 
(adherent and floating cells); 
- A future attempt to confirm the expression of ABCB5 could involve transfection of 
any cell line with a plasmid containing the ABCB5 gene. This would be invaluable to 
future cancer research and further exploration of resistance mechanisms;  
- Determination of the resistant population over-expressing the ABC transporters 
(ABCG2, ABCB1 and ABCB5) using fluorescent-activated cell sorting (FACS); 
- Once this is determined, characterization of this population could be done to detect 
“stemness” markers; 
- This population could then be expanded and further characterized over a timeframe to 
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A. Dulbecco’s modified Eagle’s medium (DMEM) 
75 
 
Weight out DMEM powder: 27,1g and NaHC02: 7.4g 
Measure out 90% 1800ml of dH20 
Add powders and stir 
Make up water up to 2L 
Adjust pH to 7.4 
Filter sterilise immediately using a 0.22µ filter 
Aliquot into 500ml bottles 
Store at 4oC 
 
B. Heat inactivation of  Fetal Calf serum (FCS) 
Thaw FCS 
Heat at 56oC for 20min 
Cool to room temperature 
Store at -20oC 
 
C. Antibiotics: Penicillin/Streptomycin 
Weight out: 6mg penicillin and 10mg od streptomycin 
Dissolve in 1L of dH20 
Sterile filter through 0.22µ filter 
Aliquot out working volumes 
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Store at -20oC 
Dilute 1:100 for routine use. 
 
D. Hypericin 
Hypericin stock (2mM) is made up in DMSO and stored at -80oC 
Working stock 20µM is made up in 1xPBS  
Equation used to calculate relative volumes of hypericin 
Ci x Vi= Cf x Vf for 3µM of HYP 
 
E.  Dacarbazine (DTIC) 
                  DTIC working stock (10mM) is made up in 0.9% NaCl and stored at -20oC 
                  It is made by weighing out 0.018218g of DTIC and dissolving it into 10ml 
                   0.9% NaCl 
                  Equation used to calculate relative volumes of DTIC 




F. Phosphate Buffer Saline (1xPBS, pH 7.4) 
Weigh out: 8g NaCl (0.14M); 1.26g Na2HPO4 anhydrous (8.8M); 0.2g KCL 
(2.7M); 0.2g KH2PO4 (1.47M) 
77 
 
Dissolve the above in 800ml dH20 
Adjust pH to 7.4 
Add dH20 up to 1L 
Autoclave in 500ml bottles 
 
G. Trypsin (0.05%)/ EDTA (0.02%) in 1xPBS 
Weigh out 0.05g Trypsin and 0.02g EDTA 
Dissolve trypsin in 100ml PBS 
Add EDTA and dissolve 
Sterilise by filtering through 0.22µ filter 
Aliquot into 50ml tubes 
Store at -20oC  
 
H. Components of  RIPA complete extraction buffer 
CPIC tablets (complete Protease inhibitor Tablets) 
Dissolve 1 tablet in 2ml dH20 for a 25x stock 
Aliquot (100µl) and store at -20oC 
Pepstatin (comes as liquid) 




Powder stored at 4oC 
Dissolve 1mg powder in 1m dH20 
Aliquot (100µl) and store at -20oC 
0.1M PMSF (phenylmethylsulfonicfluoride) 
Dissolve 0.087g in 5ml isopropanol 
Store in a dark bottle at RT or aliquot (100µl) and store at -20oC 
 
I. RIPA buffer ( in 50ml) 
From each stock: 
Take 1.5ml of NaCl (5M) 
Add 500µl of Triton X-100 (100%)  
500µl SDS (10%) 
1ml Tris, pH 7.5 (1M) 
Add 0.5g Deoxycholate  
Add 46.5ml dH20 
Filter sterilise through a 0.45 filter 
                  Store in aliquots at 4oC 
 
J. RIPA Complete Extraction Buffer (500µl) 
From each stock: 
79 
 
Take 20µl CPIC (25x) 
Add 0.5µl Aproptinin (1mg/ml) 
2.5µl PMSF (100mM) 
0.5µl Pepstatin A 
And 476µl RIPA buffer 
 
K. Western blotting 
Resolving gel buffer (1.5M Tris pH 8.8, 0.4% SDS) 
Weigh out: 36.342g Tris and 0.8g SDS 
(Wear mask when weighing out!! Be careful) 
Add it in 190ml dH20 
Heat slightly to dissolve (+/- 190ml) 
Add 180 drops concentrated HCL to pH 
Then make up to 200ml final volume 




Stacking gel buffer (0.5M Tris pH 6.8, 0.4% SDS) 
Weigh out: 6.057g tris 
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Add 0.4g SDS (wear mask when weighing out) 
Add 90ml of ddH20 
 
10x Running buffer (0.25M Tris, 1.92M Glycine, 1% SDS) 
Weigh out: 30.2g Tris and 144g Glycine 
10g SDS (wear mask when weighing out) 
Make up to 1L with ddH20 
 
1x Running buffer (0.025M Tris, 0.192M Glycine, 0.01%SDS) 
Take 100ml of 10x running buffer 
Add 900ml of ddH20 
 
10x Transfer buffer (0.31M Tris, 1.92M Glycine) 
Weigh out: 144g glycine and 38g of Tris 
Make up to 1L with ddH20 
Store at 4oC 
 
 
1x Transfer buffer (0.031M Tris, 0.192M Glycine) 
Take 100ml of 10x Transfer buffer 
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Add to it 700ml ddH20 
Then, add methanol/isopropanol (methanol can be technical grade) 
 
10x Tris Buffered Saline (TBS) pH 7.5 
Weigh out: 60.5g Tris and 87.6g NaCl 
Dissolve in 700ml of ddH20 
Then pH to 7.5 




Take 100ml of 10x TBS pH 7.5 
Add 900ml of ddH20 





5x Loading Buffer (LB) 
Weigh out 1.75g Tris 
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Add 30ml of glycerine 
Make it up to 40ml with ddH20 
pH it to 6.8 with 1N HCL 
Add 5g SDS/SLS 
Make up to 50ml 
 
5x Loading dye 
Heat up 5x loading buffer to allow SDS precipitate to dissolve 
Mix with 100µl 5x loading buffer (2 parts) 
50µl β-mercaptoethanol (1 part) 
50µl 0.025% bromophenol blue (1 part) 
Use at 1x loading dye on the gel. 
 
Ponceau S stain (0.1% (w/v) ponceau S in 5% (v/v) acetic acid) 
Weigh 1g Ponceau S 
Add 50ml acetic acid 
Make up to 1L with ddH20 
Store at 4oC. Do not freeze 
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